+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID07321808

Study of Immune Response and Safety of the Recombinant Herpes Zoster Vaccine in Adults and Children with Weakened Immune Systems

Led by Fondazione IRCCS Policlinico San Matteo di Pavia · Updated on 2026-03-05

300

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Herpes zoster HZ is a serious health problem that becomes more common and severe as the immune system weakens due to age or immunocompromised IC conditions. The immune response involving T cells and B cells is important to prevent reactivation of the virus. This study focuses on understanding how the new recombinant zoster vaccine RZV triggers immune responses in frail patients with weakened immunity, including those with cancer, immune diseases, or on immune-targeting treatments. The goal is to better understand vaccine responses in these high-risk groups, including some pediatric patients, to improve prevention strategies. The study is an observational, multicenter prospective cohort study assessing the immune response to two doses of RZV vaccination. It includes patients with rheumatologic, oncologic, neurologic, and hematologic conditions. The study will evaluate humoral antibody and cell-mediated immune responses after vaccination. Researchers will monitor vaccine safety by tracking local and systemic reactions for four weeks after the second dose and will follow participants for one year to observe immune response changes and any herpes zoster reactivation. Participants will be observed over time with blood tests to measure specific antibody levels and T cell responses at baseline and one month after the second vaccine dose. Researchers will assess the proportion of patients who show a significant antibody increase, immune response across different patient groups, and vaccine safety. The study aims to identify immune profiles linked to higher risk of viral reactivation and guide preventive treatments. Participation involves regular immune assessments and monitoring for any vaccine-related side effects, with the study expected to continue until May 2027.

CONDITIONS

Brief Title

Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients

Research Team

F

Fausto Baldanti, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here